Lee A. Dawson

University of Cambridge — United Kingdom

Neuroscience · Life Sciences

42h-index5.1kcitations140works4.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroscience and Neuropharmacology Research(48), Neurotransmitter Receptor Influence on Behavior(47), Receptor Mechanisms and Signaling(41), Neuropeptides and Animal Physiology(11), Treatment of Major Depression(10)

Publications140 total

Discovery of Potent, Selective, and Brain-Penetrant Small Molecule CD38 Inhibitors
ACS Medicinal Chemistry Letters·2026Open Access
NETSseq unveils deep molecular insights into astrocyte function in Alzheimer's disease in the human brain
Alzheimer s & Dementia·2025Open Access
CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3‐Mediated Neuroinflammation in Neurodegenerative Disease: A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics.
Alzheimer s & Dementia·2025Open Access
NETSseq reveals inflammatory and aging mechanisms in distinct cell types, driving cerebellar decline in ataxia telangiectasia
Frontiers in Neuroscience·2025· 1 citedOpen Access
NETSseq Reveals Inflammatory and Aging Mechanisms in Distinct Cell Types Driving Cerebellar Decline in Ataxia Telangiectasia
2025Open Access
A First-in-Human Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation (P8-3.016)
Neurology·2025
NETSseq Identifies Novel Therapeutic Targets for Neurodegenerative Diseases (P3-3.008)
Neurology·2025
Solengepras (CVN424): A Novel GPR6 Inhibitor in Clinical Development as an Investigational Therapy for Parkinson’s Disease (P11-5.017)
Neurology·2025
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial
EClinicalMedicine·2024· 6 citedOpen Access
Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase
Journal of Medicinal Chemistry·2024· 8 citedOpen Access
Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment
ACS Medicinal Chemistry Letters·2024· 7 citedOpen Access
Differential contribution of THIK-1 K+ channels and P2X7 receptors to ATP-mediated neuroinflammation by human microglia
Journal of Neuroinflammation·2024· 23 citedOpen Access
Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
Bioorganic & Medicinal Chemistry Letters·2024· 11 citedOpen Access
NETS‐seq advances the understanding of neuronal vulnerability in AD progression facilitating the identification of novel therapeutic targets at the single cell type level
Alzheimer s & Dementia·2023· 1 citedOpen Access
Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists
Journal of Medicinal Chemistry·2023· 4 cited
Discovery of <b>CVN417</b>, a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction
Journal of Medicinal Chemistry·2023· 5 citedOpen Access
A Covalent Binding Mode of a Pyrazole‐Based CD38 Inhibitor
Helvetica Chimica Acta·2023· 1 cited
CCDC 2246762: Experimental Crystal Structure Determination
The Cambridge Structural Database·2023Open Access
Discovery of <b>CVN636</b> : A Highly Potent, Selective, and CNS Penetrant mGluR <sub>7</sub> Allosteric Agonist
ACS Medicinal Chemistry Letters·2023· 8 citedOpen Access
CVN766 – Selective Ox1R antagonist shows efficacy in pre-clinical models of schizophrenia
Neuroscience Applied·2023Open Access
page 1 of 7Next →

Frequent Co-authors

Lee E. Schechter(8), Huy Q. Nguyen(8), Laurent Lacroix(7), Zoë A. Hughes(7), Jane Gartlon(6), Marie L. Woolley(6), Declan N.C. Jones(5), Eric Southam(5), Christian Heidbreder(5), Sharon Rosenzweig‐Lipson(5), Jim J. Hagan(5), Jane E. Cluderay(4), Neil Upton(4), Jeannette M. Watson(4), Chad E. Beyer(4), Claire S Shilliam(4), James N.C. Kew(4), A.R. Atkins(3), Warren D. Hirst(3), Pippa L Pugh(3)